## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (Currently amended) A tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:

$$R^1N$$
  $X$   $(I)$ 

wherein

R<sup>1</sup> represents hydrogen or C<sub>1-6</sub> alkyl;

X represents  $-N(H)Y^1$ ,  $-N(H)-C_{1-6}$  alkylene $Y^1$ , biphenyl or  $C_{1-6}$  alkyl substituted by biphenyl;

wherein

said biphenyl is substituted by  $Z^1$ ,  $Z^2$  and or  $Z^3$ ;

 $Y^1$  represents biphenyl substituted by  $Z^3$ ,  $Z^4$  and or  $Z^5$ ;

 $Z^1$  and  $Z^2$  are identical or different and represent hydrogen, halogen, carboxy, nitro,  $C_{1.6}$  alkyl optionally substituted by cyano or mono-,

di-, or tri- halogen,  $C_{1-6}$  alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen,  $C_{1-6}$  alkylthio, amino,  $C_{1-6}$  alkylamino, di( $C_{1-6}$  alkyl)amino,  $C_{1-6}$  alkylsulfinyl,  $C_{1-6}$  alkoxycarbonyl;

- $Z^3$  represents hydrogen, halogen, amino, pyrrolidinyl, piperidino, piperazinyl, homopiperidino,  $C_{1-6}$  alkoxy optionally substituted by mono-, di-, or tri- halogen, or  $C_{1-6}$  alkyl optionally substituted by mono-, di-, or tri- halogen;
- z<sup>4</sup> represents halogen, carboxy, nitro,  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen,  $C_{1-6}$  alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen,  $C_{1-6}$  alkylthio, amino,  $C_{1-6}$  alkylamino, di( $C_{1-6}$  alkyl)amino,  $C_{1-6}$  alkylsulfinyl,  $C_{1-6}$  alkanoyl, or  $C_{1-6}$  alkoxycarbonyl; and
- z<sup>5</sup> represents hydrogen, halogen, carboxy, nitro, C<sub>1-6</sub> alkyl optionally substituted by cyano or mono-, di-, or tri- halogen, C<sub>1-6</sub> alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen, C<sub>1-6</sub> alkylthio, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>1-6</sub> alkylsulfinyl, C<sub>1-6</sub> alkanoyl, or C<sub>1-6</sub> alkoxycarbonyl;

or

Z<sup>4</sup> and Z<sup>5</sup> together with the carbon atom to which they are attached, form a benzene ring.

2. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

- R<sup>1</sup> represents hydrogen;
- X represents  $-N(H)Y^1$  or  $-N(H)-C_{1-6}$  alkylene  $Y^1$ ;
  - Y<sup>1</sup> represents

- $Z^3$  represents hydrogen, fluoro, chloro, bromo, amino, pyrrolidinyl, piperidino, piperazinyl, homopiperidino,  $C_{1-6}$  alkoxy optionally substituted by cyano or mono-, di-, or tri- halogen, or  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen;
- $Z^4$  represents halogen, carboxy, nitro,  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen,  $C_{1-6}$  alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen,  $C_{1-6}$  alkylthio, amino,  $C_{1-6}$  alkylamino, di( $C_{1-6}$  alkyl)amino,  $C_{1-6}$  alkylsulfinyl,  $C_{1-6}$  alkanoyl, or  $C_{1-6}$  alkoxycarbonyl; and
- $Z^5$  represents hydrogen, halogen, carboxy, nitro,  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen,  $C_{1-6}$  alkoxy

optionally substituted by morpholino, or mono-, di-, or tri- halogen,  $C_{1-6}$  alkylthio, amino,  $C_{1-6}$  alkylamino, di( $C_{1-6}$  alkyl)amino,  $C_{1-6}$  alkylsulfinyl,  $C_{1-6}$  alkanoyl, or  $C_{1-6}$  alkoxycarbonyl.

3. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

- R<sup>1</sup> represents hydrogen;
- X represents  $-N(H)Y^1$  or  $-N(H)-C_{1-6}$  alkylene  $Y^1$ ;
  - Y<sup>1</sup> represents

$$Z^3$$
 $Z^4$ 
 $Z^5$ 

- Z<sup>3</sup> represents hydrogen or piperidino;
- $Z^4$  represents fluoro, chloro, bromo, carboxy, nitro,  $C_{1-6}$  alkyl optionally substituted by mono-, di-, or tri- halogen,  $C_{1-6}$  alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen,  $C_{1-6}$  alkylthio, di( $C_{1-6}$  alkyl)amino,  $C_{1-6}$  alkylsulfinyl,  $C_{1-6}$  alkanoyl, or  $C_{1-6}$  alkoxycarbonyl; and

- $Z^5$  represents hydrogen, fluoro, chloro, bromo,  $C_{1-6}$  alkoxy,  $C_{1-6}$  alkylthio or  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen.
- 4. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

R<sup>1</sup> represents hydrogen;

X represents

$$Z^{3}$$
 $Z^{1}$ 
 $Z^{2}$ 

- n represents an integer selected from 0 to 6;
- $Z^1$  and  $Z^2$  are identical or different and represent hydrogen, fluoro, chloro, bromo, carboxy, nitro,  $C_{1-6}$  alkyl optionally substituted by mono-, di-, or tri- halogen,  $C_{1-6}$  alkoxy optionally substituted by morpholino, or mono-, di-, or tri- halogen,  $C_{1-6}$  alkylthio, di( $C_{1-6}$  alkyl)amino,  $C_{1-6}$  alkylsulfinyl,  $C_{1-6}$  alkanoyl, or  $C_{1-6}$  alkoxycarbonyl; and

- $Z^3$  represents hydrogen, fluoro, chloro, bromo, amino, piperidino,  $C_{1-6}$  alkoxy optionally substituted by mono-, di-, or tri- halogen, or  $C_{1-6}$  alkyl optionally substituted by cyano or mono-, di-, or tri- halogen.
- 5. (Original) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein
  - R<sup>1</sup> represents hydrogen;
    - X represents

$$Z^1$$
 $Z^2$ 
 $Z^2$ 

- n represents an integer of 0 or 1;
- $Z^1$  represents hydrogen, fluoro, chloro, bromo,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amino,  $C_{1-6}$  alkylamino, or di( $C_{1-6}$  alkyl)amino;
- $Z^2$  represents hydrogen, fluoro, chloro, bromo,  $C_{1\text{-}6}$  alkyl or  $C_{1\text{-}6}$  alkoxy: and
- Z<sup>3</sup> represents hydrogen.

6. (Currently amended) The tetrahydro-naphthalenyl derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said tetrahydro-naphthalenyl derivative of the formula (I) is selected from the group consisting of:

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4'-(trifluoromethyl)-biphenyl-3-yl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[2'-(trifluoromethyl)-biphenyl-3-yl]urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[4'-(methylthio)-biphenyl-3-yl]urea;

N-(2',3'-dichlorobiphenyl-3-yl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-(2',4'-dichlorobiphenyl-3-yl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-(4'-acetylbiphenyl-3-yl)-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[(2'-fluorobiphenyl-4-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N [(2' fluorobiphenyl 4 yl)methyl] N' (7 hydroxy-5,6,7,8 tetrahydronaphthalen 1 yl)urea;

N-[(2',6'-difluorobiphenyl-4-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;

N-[(2'-fluorobiphenyl-3-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea; N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N'-[(4'-isopropylbiphenyl-3-yl)methyl]urea; and

N-[(2',4'-dichlorobiphenyl-3-yl)methyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea.

7. (Currently amended) A medicament pharmaceutical composition comprising a tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 in as an active ingredient, plus a pharmaceutically acceptable carrier.

8.	(Cancelled)
9.	(Currently amended) The medicament pharmaceutical composition as claimed in claim 7, wherein said tetrahydro-naphthalene derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.
10.	(Cancelled)
11.	(Cancelled)
12.	(Cancelled).
13.	(Cancelled)
14.	(Cancelled)
15.	(Cancelled)
16.	(Cancelled)
17.	(Cancelled)
18.	(Cancelled)
19.	(Cancelled)
20.	(Cancelled)

- 21. (Currently amended) Process A process for controlling an a urological disorder or disease in humans and animals by administration of comprising administering a VR1-antagonisticly effective amount of at lease one compound according to claim 1.
- 22. (Currently amended) Process A process for controlling pain in humans and animals by administration of comprising administering a VR1-antagonisticly effective amount of at least one compound according to claim 1.
- 23. (Currently amended) Process A process for controlling an inflammatory disorder or disease in humans and animals by administration of comprising administering a VR1-antagonisticly effective amount of at least one compound according to claim 1.
- 24. (New) A method for treatment and/or prophylaxis of a urological disorder in a human or animal, said urological disorder being selected from uninary incontinence, overactive bladder, and urge urinary incontinence, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.
- 25. (New) A method for treatment and/or control of a painful condition in a human or animal, said painful condition being selected from chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia,, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, and stroke, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.
- 26. (New) A method for treatment and/or prophylaxis of an inflammatory disorder in a human or animal, said inflammatory disorder being selected from asthma and COPD, comprising administering to a patient in need thereof an effective amount of a compound of claim 1.